IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a phase Ib/II, open label clinical study to evaluate the safety, tolerability and
antitumor activities of IN10018 in combination with standard chemotherapy in subjects with
high-grade serous ovarian cancer (including fallopian tube cancer and primary peritoneum
cancer, collectively defined as ovarian cancer).